Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN
Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN
Ionis和阿斯利康的WAINZUA獲得歐盟批准推薦，成爲HATTR-PN的首個自行治療方案
- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo
- 基於NEURO-TTRansform第3階段結果的建議，顯示WAINZUA表現出一致和持久的益處，改善了神經病變和生活質量，相對於安慰劑
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間